Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532357 · ClinicalTrials.gov registry record
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,536
- Enrollment target
NCT06532357 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,536 participants.
The verdict
NCT06532357 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,536 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications) and completed a survey were eligible for this study. Acute treatment is a short-term treatment. The aim of this retrospective analysis was to learn about the user´s satisfaction with Nurtec or the triptan. The level of satisfaction with Nurtec will be compared to the level of satisfaction with triptans. The benefit of this study is the real-life setting of the information collected. This means that the users were using the Migraine Buddy app for tracking their migraines in real life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,536 participants |
| Start Date | 2024-06-09 |
| Est. Completion | 2024-06-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06532357
The ClinicalTrials.gov registry entry for NCT06532357 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,536 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06532357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06532357 about?
NCT06532357 is a clinical study titled "A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.". The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migrain...
What is the current status of trial NCT06532357?
This trial is currently completed. The enrollment target is 1,536 participants. The study started on 2024-06-09. Estimated completion is 2024-06-10.
Who is sponsoring clinical trial NCT06532357?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.